2013
Psychotropic medication use in youth at high risk for psychosis: Comparison of baseline data from two research cohorts 1998–2005 and 2008–2011
Woods SW, Addington J, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA, Mathalon DH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, McGlashan TH. Psychotropic medication use in youth at high risk for psychosis: Comparison of baseline data from two research cohorts 1998–2005 and 2008–2011. Schizophrenia Research 2013, 148: 99-104. PMID: 23787224, PMCID: PMC3867209, DOI: 10.1016/j.schres.2013.05.019.Peer-Reviewed Original ResearchConceptsMedication use ratesCohort 2High riskCohort 1Alternative treatmentAntipsychotic prescription ratesBaseline antipsychotic useHigh-risk patientsEfficacy of antipsychoticsRate of prescriptionPsychotropic medication useChlorpromazine equivalent doseDuration of treatmentUse ratesNonpsychotic conditionsAntipsychotic dosesMedian ageMedication usePrescription ratesAntipsychotic prescriptionsAntipsychotic useAntipsychotic treatmentPsychotropic medicationsHigh-risk youthPsychiatric disorders
2012
Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies
Woods SW, Walsh BC, Hawkins KA, Miller TJ, Saksa JR, D'Souza DC, Pearlson GD, Javitt DC, McGlashan TH, Krystal JH. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. European Neuropsychopharmacology 2012, 23: 931-940. PMID: 23089076, PMCID: PMC4028140, DOI: 10.1016/j.euroneuro.2012.09.008.Peer-Reviewed Original ResearchConceptsPilot studyRisk syndromeSyndrome patientsNegative symptomsShort-term pilot studyEffect sizeAdjunctive antipsychotic medicationOpen-label studyPatients meeting criteriaNMDA receptor functionDurability of effectPsychosis risk symptomsGlycine site agonistsGroup effect sizesWeeks of evaluationAntipsychotic medicationSyndrome subjectsPromising effect sizesTreatment needsLarge effect sizesMeeting criteriaCognitive impairmentReduced symptomsReceptor functionSymptoms